FDA releases guidance on asthma drugs with LABAs and corticosteroids

02/18/2010 | Los Angeles Times (tiered subscription model)

The FDA advised doctors to stop prescribing asthma drugs with both long-acting beta agonists and inhaled corticosteroids because there is a risk of aggravating symptoms. LABAs should always be administered through a combination product and taken for the shortest possible time by patients who do not respond to other asthma treatments, according to the FDA's guidance.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park